Eli Lilly CEO John Lechleiter Rules Out Mega-merger Or Major Push Into Generics, Outlines Strategy Aimed At China's 21st Century Rise In An Interview With PharmAsia News
Eli Lilly's chief executive officer, John Lechleiter, recently discussed with PharmAsia News' China bureau the Indianapolis-headquartered outfit's strategy to benefit from the rapid rise of China's economy and scientific capabilities while also spelling out that the company would not seek to engineer any mega-merger ahead. The organic chemist who heads Lilly suggested in a keynote talk in Shanghai that Chinese scientists would increasingly help shape "the century of human medicine" if the government strengthens the intellectual property regime in order to unleash innovation (PharmAsia News, April 02, 2010), and expanded on those ideas in a follow-up interview.
Keep up with the top pharma business news of the week. On the go.
More from Archive
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
